Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 56-60

  Lessem, Erica ^a   Cox, Helen ^b   Daniels, Colleen ^a   Furin, Jennifer ^c   McKenna, Lindsay ^a   Mitnick, Carole D ^d   Mosidi, Thato ^e   Reed, Caitlin ^f   Seaworth, Barbara ^g   Stillo, Jonathan ^h   Tisile, Phumeza ⁱ   von Delft, Dalene ^e  

^a Treatment Action Group   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e TB Proof   (South Africa)

^f OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h CITY UNIVERSITY OF NEW YORK   (United States)

ⁱ Independent activist   (South Africa)

Author keywords

Access; Community; Compassionate use; Drugs; Multidrug resistant tuberculosis; Tuberculosis

Indexed keywords

BEDAQUILINE; DELAMANID; LINEZOLID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIMICROBIAL THERAPY; COMPASSIONATE USE; DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG RESISTANT TUBERCULOSIS; DRUG SURVEILLANCE PROGRAM; HEALTH CARE ACCESS; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PATENT; REGISTRATION; REVIEW; VULNERABLE POPULATION; ECONOMICS; HEALTH CARE DELIVERY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; COMPASSIONATE USE TRIALS; DIARYLQUINOLINES; HEALTH SERVICES ACCESSIBILITY; HUMANS; LINEZOLID; NITROIMIDAZOLES; OXAZOLES; TUBERCULOSIS, MULTIDRUG-RESISTANT; VULNERABLE POPULATIONS;

EID: 84925275260     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.12.012     Document Type: Review

References (33)

1. Global tuberculosis report 2014 2014, World Health Organization, World Health Organization, Geneva, Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1. (Accessed 12 November 2014).
2. Food and Drug Administration (U.S.). FDA approves first drug to treat multi-drug resistant tuberculosis [Internet]. 2014 [9 June 2014]. Available from: . http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm.
3. European Medicines Agency. Deltyba [Internet]. 2014 [9 June 2014]. Available from: . http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002552/human_med_001699.jsp%26mid=WC0b01ac058001d124.
4. Cox H., Hughes J., Daniels J., Azevedo V., McDermid C., Poolman M., et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. 2014, 18(4):441-448.
5. World Health Organization. The END TB strategy [Internet]. 2014 [October]. Available from: . (Accessed 12 November 2014). http://www.who.int/tb/post2015_TBstrategy.pdf?ua=1.
6. Horsburgh C.R., Haxaire-Theeuwes M., Lienhardt C., et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013, 17(2):146-152.
7. Review of the national tuberculosis programme in the Republic of Moldova 2013, World Health Organization, World Health Organization Regional Office for Europe, Copenhagen, Available from: http://www.euro.who.int/__data/assets/pdf_file/0003/236154/e96959.pdf?ua=1. (Accessed 12 November 2014).
8. Global tuberculosis report 2014 2014, World Health Organization, World Health Organization, Geneva, Available from: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf. (Accessed 12 November 2014).
9. Ibid.
10. Conradie F., Meintjes G., Hughes J., Maartens G., Ferreira G., Siwendu S., et al. Clinical Access to bedaquiline programme of drug-resistant tuberculosis. S Afr Med J 2014, 104(3):164-166.
11. Esposito S, D'Ambrosio L, Tadolini M, et al. European Respiratory Society/World Health Organization Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Resp J, 00604-2014.3d 1/5/14 14:21:53.
12. World Health Organization The use of delamanid in the treatment of multidrug-resistant tuberculosis, Interim policy guidance 2014, World Health Organization, Geneva, Available from: http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1&ua=1. (Accessed 12 November 2014).
13. Pietersen E., Ignatius E., Streicher E.M., Mastrapa B., Padanilam X., Pooran A., et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet [Internet]. 2014 Jan 16, 6736(13):1-10. [cited 2014 Mar 28].
14. Lessem E. Tuberculosis Drug Development Hobbles Forward. i-Base/Treatment Action Group. 2014 pipeline report. Edited by Andrea Benzacar 2014, 197-216. Treatment Action Group, New York, Available from: http://www.pipelinereport.org/sites/g/files/g575521/f/201407/2014%20Pipeline%20Report%20Full_0.pdf. (Accessed 12 November 2014). P. Clayden, M. Harrington, T. Swan (Eds.).
15. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis, Interim policy guidance 2013, World Health Organization, World Health Organization, Geneva, Available from: http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf. (Accessed 23 September 2014).
16. The use of delamanid in the treatment of multidrug-resistant tuberculosis, Interim policy guidance 2014, World Health Organization, World Health Organization, Geneva, Available from: http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1&ua=1. (Accessed 12 November 2014).
17. Policy implementation package for new TB drug introduction 2014, World Health Organization, World Health Organization, Geneva, Available from: http://www.who.int/tb/PIPnewTBdrugs.pdf?ua=1. (Accessed 12 November 2014).
18. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient 2012, World Health Organization, World Health Organization, Geneva, Available from: http://www.who.int/medicines/publications/Pharmaco_TB_web_v3.pdf. (Accessed 23 September 2014).
19. Companion handbook to the 2011 WHO guidelines for the programmatic management of drug-resistant tuberculosis 2014, World Health Organization, World Health Organization, Geneva, Available from: http://www.who.int/tb/publications/pmdt_companionhandbook/en/. (Accessed 23 September 2014).
20. Partners In Health. A new partnership to change MDR-TB treatment around the world [Internet]. 2014 [10 June 2014]. Available from: . http://www.pih.org/blog/a-new-partnership-to-change-mdr-tb-treatment-around-the-world.
21. The Global Fund. Eligibility list 2014. Available from: . (Accessed 24 November 2014). http://www.theglobalfund.org/en/fundingmodel/single/eligibility/.
22. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance 2013, World Health Organization, World Health Organization, Geneva, Available from: http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf. (Accessed 13 November 2014).
23. Doctors Without Borders [MSF]. New hope to beat XDR-TB with linezolid- but high price keeps it out of reach [Internet]. 2013 [29 August 2013]. Available from: . https://www.msf.org.za/msf-publications/new-hope-to-beat-xdr-tb-with-linezolid-high-price-keeps-it-out-reach.
24. Tuberculosis surveillance and monitoring in Europe 2014 2014, European Center for Disease Prevention and Control/WHO Regional Office for Europe, European Center for Disease Prevention and Control, Stockholm, Available from: http://www.ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2014.pdf. (Accessed 13 November 2014).
25. Shaw K.J., Barbachyn M.R. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011 Dec, 1241:48-70.
26. Gler M.T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J.L., Vargas-Vasquez D.E., et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012, 366(23):2151-2160.
27. Diacon A.H., Pym A., Grobusch M.P., de los Rios J.M., Gotuzzo E., Vasilyeva I., et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014, 371(8):723-732.
28. Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012, 16(4):447-454.
29. Sotgiu G., Centis R., D'Ambrosio L., Alffenaar J.W., Anger H.A., Caminero J.A., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012, 40(6):1430-1442.
30. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance 2013, World Health Organization, World Health Organization, Geneva, Available from:, (Accessed 13 November 2014). http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf.
31. Package leaflet: Information for the patient: Sirturo 100mg tablets: Bedaquiline 2014, Janssen-Cilag International NV, Janssen-Cilag International NV, Belgium, Available from:, (Accessed 13 November 2014). http://www.medicines.org.uk/emc/PIL.%2028691.latest.pdf.
32. Kahn, Tamar. Bedaquiline approved to treat multidrug-resistant tuberculosis [Internet]. Business Day Live [21 October 2014]. Available from: . (Accessed 13 November 2014). http://www.bdlive.co.za/national/health/2014/10/21/bedaquiline-approved-to-treat-multi-drug-resistant-tuberculosis.
33. Blanc F.X., Sok T., Laureillard D., Borand L., Rekacewicz C., Nerrienet E., et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011, 365(16):1471-1481.